Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4876 - 4900 of 5886 in total
Rosa centifolia flower oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Investigational
Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration...
Investigational
Experimental
Fluorocyclopentenylcytosine is under investigation in clinical trial NCT03189914 (RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer).
Investigational
H3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).
Investigational
Investigational
Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.
Investigational
Nutraceutical
Ceftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine. It is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product. It is resistant to hydrolysis by beta-lactamase, and has activity...
Vet approved
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).
Investigational
Experimental
Experimental
Experimental
A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.
Experimental
Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Investigational
Investigational
Displaying drugs 4876 - 4900 of 5886 in total